AstraZeneca Launches Phase 3 THARROS Trial of Breztri to Reduce Cardiopulmonary Events in COPD.

AstraZeneca has launched the Phase 3 THARROS trial to evaluate the potential of the inhaled triple therapy Breztri (budesonide/glycopyrronium/formoterol fumarate [BGF]) in reducing adverse cardiopulmonary events in individuals with chronic obstructive pulmonary disease (COPD). The trial will enroll approximately 5000 individuals aged 40 to 80 years with COPD and cardiopulmonary risk. The primary endpoint of the trial will be a composite endpoint that combines cardiac and respiratory outcomes. If successful, the trial could provide critical evidence for the use of triple combination therapy in reducing severe cardiopulmonary events in COPD patients. AstraZeneca has also announced the initiation of a second Phase 3 trial, ATHLOS, which will investigate the effects of BGF on cardiopulmonary parameters in COPD patients with exertional breathlessness. [Extracted from the article]

Copyright of Patient Care (Online) is the property of MJH Life Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)